Trial · NCT00395291
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in IGF-1 After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | 92.7 | Standard Deviation 62.3 | ng/ml | |
| Change in IGF-1 After 30 Days of Intervention Compared to Baseline Level. | Placebo | 6.7 | Standard Deviation 40.2 | ng/ml | |
| Change in Acyl-Ghrelin After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | -23.4 | Standard Deviation 68.9 | pg/ml | |
| Change in Acyl-Ghrelin After 30 Days of Intervention Compared to Baseline Level. | Placebo | 3.5 | Standard Deviation 150.3 | pg/ml | |
| Change in Leptin After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | 24.4 | Standard Deviation 50.2 | ng/ml | |
| Change in Leptin After 30 Days of Intervention Compared to Baseline Level. | Placebo | -6.9 | Standard Deviation 30.4 | ng/ml | |
| Change in Insulin After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | 3.77 | Standard Deviation 10.5 | uIU/ml | |
| Change in Insulin After 30 Days of Intervention Compared to Baseline Level. | Placebo | -.2 | Standard Deviation 12.5 | uIU/ml | |
| Change in Des-Acyl Ghrelin After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | 30.2 | Standard Deviation 201.5 | pg/ml | |
| Change in Des-Acyl Ghrelin After 30 Days of Intervention Compared to Baseline Level. | Placebo | -44.05 | Standard Deviation 157.4 | pg/ml | |
| Change in TNF-alpha After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | 1.2 | Standard Deviation 5.9 | pg/ml | |
| Change in TNF-alpha After 30 Days of Intervention Compared to Baseline Level. | Placebo | -0.7 | Standard Deviation 14.6 | pg/ml | |
| Change in CRPs After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | 2.6 | Standard Deviation 13.4 | mg/ml | |
| Change in CRPs After 30 Days of Intervention Compared to Baseline Level. | Placebo | 6.0 | Standard Deviation 32.7 | mg/ml | |
| Change in IL-1 After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | 0.0 | Standard Deviation 0.2 | pg/ml | |
| Change in IL-1 After 30 Days of Intervention Compared to Baseline Level. | Placebo | -0.0 | Standard Deviation 0.3 | pg/ml | |
| Changes in the Following Level: IL-6 | MK-0677 | 3.1 | Standard Deviation 5.2 | pg/mL | |
| Changes in the Following Level: IL-6 | Placebo | 0.8 | Standard Deviation 6.9 | pg/mL | |
| Change in IL-10 After 30 Days of Intervention Compared to Baseline Level. | MK-0677 | -0.1 | Standard Deviation 1.9 | pg/ml | |
| Change in IL-10 After 30 Days of Intervention Compared to Baseline Level. | Placebo | 0.7 | Standard Deviation 1.7 | pg/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00395291/results